Skip to content
Screener

Novavax NVAX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Moderna logo
ModernaMRNA
$19M+26.7%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$6.09M-0.7%
ALN
Alnylam PharmaceuticalsALNY
$45.93M-0.4%
Roivant Sciences logo
Roivant SciencesROIV
$12.38M+31.7%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$453K-21.9%
TTR
Turn Therapeutics Inc.TTRX
$47.8K

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.31B+0.5%
Enterprise value$1.42B+27.9%
P/S3.2×+2.0×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Novavax’s 10-K, filed February 26, 2026.

Filed
Feb 26, 2026, 7:33 AM EST
Fiscal year
FY2025
Accession
0001000694-26-000007
Lease Assets and LiabilitiesClassificationDecember 31, 2025December 31, 2024
ROU assets, finance, netRight-of-use asset, net2,565139,739
Total non-current ROU assets$22,897$161,585
Liabilities:
Current portion of operating lease liabilitiesOther current liabilities$9,878$10,094
Current portion of finance lease liabilitiesCurrent portion of finance lease liabilities2,5077,009
Total current lease liabilities$12,385$17,103
Non-current portion of operating lease liabilitiesOther non-current liabilities$19,359$22,958
Non-current portion of finance lease liabilitiesNon-current finance lease liabilities2,09153,726

Item 16. FORM 10-K SUMMARY

FAQ

What is Novavax's operating lease liabilities (current)?
Novavax (NVAX) reported operating lease liabilities (current) of $9.88M in Q4 2025.
How has Novavax's operating lease liabilities (current) changed year-over-year?
Novavax's operating lease liabilities (current) decreased by 2.1% year-over-year, from $10.09M to $9.88M.
What is the long-term trend for Novavax's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Novavax's operating lease liabilities (current) has grown at a 21.2% compound annual growth rate (CAGR), from $3.78M to $9.88M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Novavax's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude